Form 3/A - Initial statement of beneficial ownership of securities: [Amend]
SEC Accession No. 0001104659-25-001671
Filing Date
2025-01-07
Accepted
2025-01-07 16:10:10
Documents
1
Period of Report
2024-04-17

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm251864-12_3aseq1.html 3/A  
1 OWNERSHIP DOCUMENT tm251864-12_3aseq1.xml 3/A 5718
  Complete submission text file 0001104659-25-001671.txt   7587
Mailing Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019
Business Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019 201-488-0460
BRAINSTORM CELL THERAPEUTICS INC. (Issuer) CIK: 0001137883 (see all company filings)

EIN.: 207273918 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O BRAINSTORM CELL THERAPEUTICS INC. 1325 AVENUE OF AMERICAS, 28TH FLOOR NEW YORK NY 10019
Business Address
Dagher Ibrahim B. (Reporting) CIK: 0002019599 (see all company filings)

Type: 3/A | Act: 34 | File No.: 001-36641 | Film No.: 25514970